A Cancer Drug Lowered Brain Spread of Lung Cancer in Lab Tests
Original title: Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in lab dishes and in animals, not in people.
The short version
A drug that is already approved for some cancers stopped lung cancer from taking hold in the brain, but so far only in lab dishes and animals.
What was studied. Researchers looked at lung cancer that spreads to the brain. They tested lung cancer cells in the lab and in animals, and they studied a protein on the cells called NTRK.
What they found. The lung cancer cells had a normal, unchanged form of NTRK. Signals from the brain switched this protein on and helped the cancer cells grow. A drug called entrectinib blocked those signals and slowed the cells down. In animals, it kept the cancer from settling and growing in the brain. It did not have a big effect on cancer outside the brain.
What this means, and what it doesn't
What it could mean: This points to a possible new way to protect the brain in lung cancer. The drug used here is already approved for other cancers, so it is well known to doctors. Researchers now have a reason to study it for this purpose.
What it doesn't mean: This does not mean the drug works this way in people. The work was done in lab dishes and in animals. Many things that work in animals do not work in humans. It has not been tested in patients for this use, and it is not approved for it. It is not a cure. Do not ask for this treatment based on this study. Talk to your care team about the options that are proven today.
Source: PubMed, August 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.